Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimers diseaseShow others and affiliations
2017 (English)In: Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, E-ISSN 1091-6490, Vol. 114, no 49, p. 13018-13023Article in journal (Refereed) Published
Abstract [en]
The molecular architecture of amyloids formed in vivo can be interrogated using luminescent conjugated oligothiophenes (LCOs), a unique class of amyloid dyes. When bound to amyloid, LCOs yield fluorescence emission spectra that reflect the 3D structure of the protein aggregates. Given that synthetic amyloid-beta peptide (A beta) has been shown to adopt distinct structural conformations with different biological activities, we asked whether A beta can assume structurally and functionally distinct conformations within the brain. To this end, we analyzed the LCO-stained cores of beta-amyloid plaques in postmortem tissue sections from frontal, temporal, and occipital neocortices in 40 cases of familial Alzheimers disease (AD) or sporadic (idiopathic) AD (sAD). The spectral attributes of LCO-bound plaques varied markedly in the brain, but the mean spectral properties of the amyloid cores were generally similar in all three cortical regions of individual patients. Remarkably, the LCO amyloid spectra differed significantly among some of the familial and sAD subtypes, and between typical patients with sAD and those with posterior cortical atrophy AD. Neither the amount of A beta nor its protease resistance correlated with LCO spectral properties. LCO spectral amyloid phenotypes could be partially conveyed to A beta plaques induced by experimental transmission in a mouse model. These findings indicate that polymorphic A beta-amyloid deposits within the brain cluster as clouds of conformational variants in different AD cases. Heterogeneity in the molecular architecture of pathogenic A beta among individuals and in etiologically distinct subtypes of AD justifies further studies to assess putative links between A beta conformation and clinical phenotype.
Place, publisher, year, edition, pages
NATL ACAD SCIENCES , 2017. Vol. 114, no 49, p. 13018-13023
Keywords [en]
Alzheimer; amyloid; neurodegeneration; prion; strains
National Category
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
Identifiers
URN: urn:nbn:se:liu:diva-143910DOI: 10.1073/pnas.1713215114ISI: 000417339700048PubMedID: 29158413OAI: oai:DiVA.org:liu-143910DiVA, id: diva2:1170033
Note
Funding Agencies|EC Joint Programme on Neurodegenerative Diseases (JPND-REfrAME); NIH [P50-AG025688, RR00165, OD11132, P30-AG010133]; Public Health Service Grant [P30-AG010133]; Alexander von Humboldt Foundation; Goran Gustafsson Foundation; Swedish Research Council; University College London Hospitals-National Institute for Health Research Biomedical Research Centre; Alzheimers Research UK
2018-01-022018-01-022019-11-08